FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 933 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... September 6, 2024 EMA Recommends Extension of Indications for Tegafur December 24, 2021 Do Black Lives Matter Less Than Those of Cancer Survivors? June 18, 2020 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 Load more HOT NEWS Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... Studying “Total Diet” and Its Impact on Health, Including Cancer Risk
